Statins: turning down cholesterol production
Most of your cholesterol is made in the liver, not eaten. A statin (the '-statin' drugs, e.g. atorvastatin, simvastatin) blocks HMG-CoA reductase, the rate-limiting enzyme of that synthesis. With less cholesterol made internally, the liver pulls more LDL ('bad' cholesterol) out of the blood. Over years this slows the fatty plaques that narrow arteries and trigger heart attacks and strokes.
Two ways blood clots — and two drug families
A clot forms in two stages. First platelets stick to a damaged vessel and clump — the fast 'white clot' of arteries. Then clotting factors weave a fibrin mesh — the slower 'red clot' of veins. Each stage has its own drug family: antiplatelets for the platelet plug, anticoagulants for the fibrin mesh.
An antiplatelet like low-dose aspirin makes platelets less sticky — used to prevent arterial events such as heart attacks. An anticoagulant like warfarin or the newer direct oral agents slows fibrin formation — used to prevent venous clots and the strokes of atrial fibrillation. They thin the blood by different mechanisms, so doctors choose by which kind of clot they fear.
vessel injury
|
platelets stick & clump <-- antiplatelets (e.g. aspirin)
| [arterial 'white clot']
clotting factors -> fibrin mesh <-- anticoagulants (e.g. warfarin)
[venous 'red clot']
established clot -> thrombolytic dissolves it (emergency)The trade-off: every blood-thinner bleeds
Stopping clots and stopping bleeding are the same machinery, so every one of these drugs trades clot protection against bleeding risk. Warfarin is the sharpest example: a narrow therapeutic index, many food and drug interactions, and a need for regular blood-test monitoring (the INR). Its antidote is vitamin K; direct oral anticoagulants are easier to use but their reversal agents are newer and costlier.